Positioning political selling, disclosed 2026-09-11
Options put/call open interest 1.44, read 2026-10-30
Ethical passes the values gate
Price149.89 USD
Fair value210.00
Ethical score89.5/100
RatingOPPORTUNITY
Our investment reviews on this name
2026-10-23Read Accumulation147.31+1.8% to today ✓Markdown gives way to Accumulation
2026-10-22Read Markdown147.31+1.8% to today Accumulation gives way to Markdown first Markdown read since October
2026-10-19Read Accumulation147.31+1.8% to today ✓Markdown gives way to Accumulation with volume flow in agreement
2026-09-21Read Markdown150.72-0.6% to today ✓Distribution gives way to Markdown after an 11% slide in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Align Technology holds its Accumulation at $149.89. Consolidating, no directional conviction, held for 290 days.
As held on the ledger · 2026-10-30
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 290 days
Price at the screen
$149.89
Valuation
21.85 trailing · 12.15 forward price to earnings
Values screen
PASS· score 89.5
Beta
1.67
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.84%
Below 33%
Interest-bearing debt is just 1.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
35.24%
Below 49%
Money owed to the company is 35.2% of assets, under the 49% limit.
Pass
Revenue purity
0.40%
Below 5%
Only 0.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Align Technology clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Read as at 2026-10-30. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ALGN's ethical verdict changes
Today ALGN passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads OPPORTUNITY: it trades at roughly a 40% discount to our $210.00 fair value, moderate competitive moat, 1.90% revenue growth.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. A 40.1% margin of safety to the base estimate.
Third-party analyst targets: 14 covering, consensus Buy. The average target sits +27% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clear aligners priced below their worth
Think of Align as the firm that quietly swapped metal braces for trays you can almost forget you are wearing. Shares trade at 14.3 times forward earnings with a 36 percent gap to our fair value, a moderate moat, and an ethical pass, even as revenue edges up 6 percent and margins hold at 10 percent.
Low returns on equity of 11 percent and single-digit growth leave little cushion if dental spending slows or rivals gain ground in the aligner market.
Analyst targets sit above the current price. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ALGN trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Accumulation$147.31+0.0%Entry 18
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (14 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$147.31+0.0%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (14 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$147.31+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (14 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$147.31+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (14 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$147.31+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (14 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (14 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown · changed$147.31+0.0%Entry 12
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (14 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$147.31+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (14 analysts) rates it buy, with a mean price target of $209. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (14 analysts) rates it buy, with a mean price target of $209.
2026-10-12Markdown$142.71-0.9%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (14 analysts) rates it buy, with a mean price target of $209.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.